Northland Capital partners view on Immupharma PLC LON:IMM: Alto’s investment further corroborates our view that ImmuPharma represents a good investment opportunity. The group’s lead drug, a potential treatment for Lupus, currently in a Phase 3 clinical trial, is expected to deliver a pivotal read-out by the end of 2017.
Alto ups its stake |
n Yesterday ImmuPharma announced that it received notification by Alto Invest and its subsidiaries confirming its holding in ImmuPharma of 4,870,367 million Ordinary Shares in the capital of the Company, representing 3.99% of the Company’s total voting rights, crossing above the 3% threshold.
n Alto Invest is an independent asset management firm regulated by the French financial markets authority and is a specialised investor in European small and mid-cap companies. |